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BLOOD TRANSPLANTATION FOR CHILDREN WITH HURLERS SYN-
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Hurlers syndrome (HS), the most severe form of mucopolysac-
charidosis type-I causes progressive deterioration of the central ner-
vous system and death in childhood. Allogeneic-stem cell
transplantation (SCT) before the age of two years halts disease pro-
gression and prolongs life. Graft-failure and mixed-chimerism (40–
50%) limit the success of SCT for HS. Unrelated-cord blood trans-
plants (UCBT) are suggested to be a good alternative option for
bone marrow, however, little is known about risk factors for out-
comes after UCBT for this disease. We have analyzed 93 HS chil-
dren that received an UCBT from 1995 to 2007 and were reported
to EUROCORD or transplanted at Duke University. Median age at
UCBT was 1.3 (0.2–4) yrs, and median follow up was 24 (3–140)
mths. The donor was HLA-identical (HLA-A and B by low resolu-
tion and HLA-DRB1 by high-resolution) in 15 cases (16%) and in-
compatible in 78 cases (84%: most with 1 (62%) and 2(34%) HLA
disparities). The median nucleated cell dose/kg and CD341/kg at
infusion were respectively 7.2 (2–22)x107 and 2.3 (0.5–17)x105.
With the exception of 5 patients, all received a Busulfan/Cyclophos-
phamide (1Fludarabine: 6) regimen. All patients received ATG or
Campath (4).
Results:Median days to neutrophil and platelet recovery were 22
(10–46) and 35 (13–82) days, respectively. Mixed-chimerism was
found in only 4%. All patients had normal enzymlevels. All patients
had normal enzyme levels after engraftment. In multivariate analy-
ses for neutrophil recovery, a CD341-dose of .2.3  105/kg (HR
5 2.0; p5 0.015) was associated with increased probability of recov-
ery. Acute-GvHD (grade II-IV) was observed in 27%, while
chronic-GvHD was seen in 10% at 2 years. Two years overall sur-
vival (OS) and disease/event free survival were 78% and 70%, re-
spectively. For 2 years OS, time from diagnosis to UCBT more
than 6 months was associated with increased risk of death (6% for
those children transplanted earlier and 30% for those transplanted
later: p5 0.04). Transplantation improved somatic features of HS.
In conclusion, outcomes following UCBT for Hurlers syn-
drome are encouraging. UCB appears to be a good alternative allo-
geneic stem cell source to transplant children with HS, and is
associated with a very low incidence of mixed-chimerism. Earlier
transplantation and higher cell dose are associated with better out-
comes after UCBT for HS patients.59
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Tumor necrosis factor-alpha (TNF-a) plays a significant role in
the conditioning related toxicities and development of acute
GvHD (aGvHD). In this study, we sought to examine if specific
polymorphisms in TNF pathway genes were associated with risk
of aGvHD. Single nucleotide polymorphisms (SNPs) in TNF-a;
and TNF receptor superfamily member 1A (TNFRSF1A) and 1B
(TNFRSF1B) were investigated; we selected SNPs with minor al-
lele frequency of $10% (13 in all) and TNF-a d microsatellite. Ina multi-institutional trial, 180 eligible patients (mean age 10 y, me-
dian 11, range 6 m-20 y) were prospectively evaluated for clinical
outcomes after 6/6 matched unrelated donor marrow transplants.
All patients received myeloablative conditioning and two drug
GvHD prophylaxis with cyclosporine or tacrolimus, majority with
methotrexate. Overall, 62% patients developed aGvHD (13%
grade I, 21% grade II, 13% grade III and 5% grade IV). Genotyping
was performed on pretransplant host peripheral blood genomic
DNA samples. TNF-a: Grade II-IV aGvHD was associated with
the variant A allele of -238 (G/A) (RR 1.7, CI 1.3, 2.5; p\ 0.01)
and variant T allele of -857 (C/T) (RR 2, CI 1.1, 3.9; p5 0.01). Se-
vere (grade III-IV) aGvHD was associated with variant A allele of -
863(C/A) (RR 2, CI 1.1, 3.3; p5 0.04) and variant C allele of -1031
(T/C) (RR 1.7, CI 1, 3.3; p5 0.05). 17/52 patients with TNF-a d3/
d3 genotype (33%) versus 68/126 with other TNF-a d genotypes
(54%) were associated with grade II-IV aGvHD (RR 0.6, CI 0.4,
0.9; p\ 0.01). TNF-a d4/d4 genotype was associated with greater
risk of aGvHD (RR 1.4, CI 1.1–1.6, p5 0.03). TNFRSF1A: No sig-
nificant correlation was observed between any of the five selected
SNPs and risk of aGvHD in this cohort. TNFRSF1B: Exon 6 cod-
ing SNP 676 (T/G) results in a juxtamembrane inversion from me-
thionine to arginine (TNFRSF1BMET/ARG); this variant is
associated with increased risk of inflammatory disorders such as lu-
pus and ulcerative colitis. 11/14 (79%) with SNP 676 (T/G) GG ge-
notype versus only 21/50 (42%) with GT and 52/109 (48%) with
TT genotypes developed grade II-IV aGvHD; the relative risk
(RR) with variant GG genotype was 1.7 (CI, 1.2, 2.4; p 5 0.02).
In conclusion, we have observed clinically important relationships
between genetic polymorphisms in TNF-a and a coding SNP in
TNFRSF1B versus occurrence and severity of acute GvHD in
this cohort. Improved understanding of this relationship may allow
for a risk-adjusted approach to GVHD prevention.60
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Introduction: Though cure rates for NHL in children and ado-
lescents are$80%, salvage rates are poor. The role of HSCT is dif-
ficult to determine from the literature as published reports include
few patients (N5 10–20) and usually from single centers.Methods:
Included are 247 patients with NHL aged#18 yrs who received au-
tologous (N5 134) or allogeneic (N5 123; 76 matched sibling and
47 unrelated donor) HSCT in 1975–2005 and reported to the Cen-
ter for International Blood and Marrow Transplant Research. Re-
sults: The median ages of patients undergoing autologous and
allogeneic transplantation were 14 years and 12 years, respectively.
23% of autologous transplants were performed in CR1, 39% in
CR2 and 38% in $CR3, relapse or induction failure. 23% of allo-
geneic transplants were performed in CR1, 33% in CR2 and 44% in
$CR3, relapse or induction failure. Patients with large cell lym-
phoma (DLBCL and ALCL) were more likely to receive autologous
HSCT, whereas those with small cell lymphoma (Burkitt and lym-
phoblastic) were more likely to receive allogeneic HSCT. Charac-
teristics of recipients of matched sibling and unrelated donor
HSCT were similar except that very few unrelated donor HSCT re-
cipients were in first clinical remission (CR1) at transplantation.
Shown below are the probabilities of transplant-related mortality
(TRM, relapse and progression-free survival (PFS) rates. The prob-
ability estimates after allogeneic HSCT for DLBCL and ALCL
should be interpreted with caution as patient numbers are small.
Further, small numbers of patients in each of the disease categories
prevented comparison of outcomes after autologous and allogeneic
HSCT. Conclusion: Autologous or allogeneic HSCT can salvage
30–50% of children and adolescents with high-risk or recurrent
NHL. TRM is are lower after autologous HSCT and relapse is
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vival rates are similar in both transplant groups.
Autologous AllogeneicOutcome Probability (95% Confidence Interval)Burkitt N 5 33 N 5 45
TRM @ 100-days 9% (2–21) 11% (4–22)
Relapse @ 5-years 54% (35–73) 47% (31–63)
PFS @ 5-years 37% (21–55) 35% (22–50)
DLBCL N 5 48 N 5 18
TRM @ 100-days 8% (2–18) 11% (1–29)
Relapse @ 5-years 28% (16–42) 33% (14–56)
PFS @ 5-years 55% (40–69) 44% (23–67)
Lymphoblastic N 5 23 N 5 40
TRM @ 100-days 9% (1–23) 25% (13–39)
Relapse @ 5-years 58% (34–81) 15% (6–28)
PFS @ 5-years 33% (15–55) 50% (35–65)
ALCL N 5 27 N 5 15
TRM @ 100-days 4% (0–14) 21% (5–43)
Relapse @ 5-years 45% (25–65) 15% (2–38)
PFS @ 5-years 43% (24–63) 55% (28–80)61
MULTI-INSTITUTIONAL PHASE II STUDY OF PENTOSTATIN FOR THE
TREATMENT OF REFRACTORY CHRONIC GVHD (cGVHD) IN CHILDREN:
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Pentostatin, an irreversible adenosine deaminase inhibitor, was
shown in a phase II study to be effective for steroid-refractory
cGVHD. Our goal was to determine efficacy and toxicity of pentos-
tatin for steroid-refractory cGVHD in children.
Eligible patients were\ 21 years, with refractory cGVHD, hav-
ing failed#2 prior regimens. Subjects were to get 4 mg/m2 pentos-
tatin IV every 2 weeks for at least 6 months. If subjects had complete
response(CR) at 6 months, pentostatin was stopped; with partial re-
sponse(PR, improvement in $1 site without progression in other)
or stable disease, treatment continued for 12 months. With progres-
sion, pentostatin was discontinued. Tapering of corticosteroids be-
gan 8–12 weeks after starting study; other immunosuppression was
tapered after 3 months. Change in GVHD status was assessed every
3 months for each involved organ(skin, oral, eyes, liver, joint, GI,
pulmonary). Grades were 0(not involved), 1(mild), 2(moderate),
and 3(severe), with subject’s last available evaluation used to deter-
mine response.
A total of 51 subjects were enrolled in 26 sites; 43 are reported(41
completed therapy/off-study; 2 on-study but . 6 months therapy).
8 are too early to evaluate. Median age was 9.5 years(0.9–20.7).
GVHD grade was moderate in 17, severe in 26. Most were receiving
corticosteroids at time of study entry(40); other immunosuppres-
sion was: MMF(23), FK-506(23), CSA(11) and other(5).
Subjects received a median of 12 pentostatin doses(range 1–26)
over a median of 6 months(0.5–12). Overall response rate was
44%(28% PR, 16% CR). 2 subjects had stable disease and 9 went
off-study before the 3-month evaluation(7 progression, 2 toxicity).
The table shows response by system in the 34 subjects that com-
pleted the 3 month evaluation. Skin and oral had the most notable
response. By study completion, 8 subjects were off corticosteroids,
and 20 were on\ 0.5 mg/kg/day. Most common severe adverse
events were infection(11 documented[bacterial 5 8, fungal5 1, vi-
ral 5 2]). Ten subjects were removed due to toxicity and 2 due to
cancer relapse; 6 had had a response to pentostatin. Four deaths oc-
curred either on-study or within 28 days after last dose from infec-
tion(3), leukoencephalopathy(1).Pentostatin has activity in the treatment of refractory cGVHD in
children, with acceptable toxicity. Skin and oral cGVHD has the
most benefit. Adding pentostatin allows significant tapering of cor-
ticosteroids. Further follow-up is needed to evaluate durability of
response.Response by System in the 34 Subjects on Study at least through 3-month
Evaluation
Total StableSystem Manifestations N Response Progression DiseaseSkin Rash/Lichenoid 29 17 9 3Fasciitis/
Sclerosis21 15 3 3Oral symptoms/
lichenoid and/or
erythema19 15 2 2Ocular symptoms/need
for treatment16 7 5 4Joints Arthralgias/
Contractures16 6 6 4Gastrointestinal Vomiting/
Abdominal Pain/
Diarrhea15 7 6 2Liver Total Bilirubin 3 0 2 162
HIGH RESOLUTION HLA TYPING AND ATG PREVENT CHILDREN WITH
ALL FROM GVHD AND TREATMENT RELATED MORTALITY AFTER UNRE-
LATED DONOR STEM CELL TRANSPLANTATION
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Graft versus Host Disease (GVHD) is still one of the most impor-
tant risk factor for mortality and long term morbidity in children
and adolescents undergoing allogeneic stem cell transplantation
(SCT) from unrelated donors (UD). In 2003 the Berlin-Frank-
furt-Muenster (BFM)-Study Group initiated a prospective, interna-
tional, multicenter trial on allogeneic SCT in children with high-
risk ALL (ALL-SCT-BFM 2003). In this ongoing trial main goals
are the standardisation and harmonisation of the SCT procedure
and the question, if SCT from a HLA-genoidentical sibling donor
(MSD) is equivalent to SCT from a matched donor (MD). A MD
was defined as related or donor with 10/10 or 9/10 HLA matches,
determined by HLA high-resolution typing (4 digits/allel: A, B,
C, DRB1 and DQB1). Between September 2003 and June 2007,
381 patients (185 in CR1, 196 in CR2 or after subsequent relapse)
were recruited by 27 participating SCT centers in Austria, Germany
and Switzerland. Indications for SCT were poor response to induc-
tion treatment, cytogenetic aberrations, early bone marrow relapse,
or any subsequent ALL relapse. GVHD-prophylaxis for patients
undergoing MSD-SCT consisted of only CSA to augment the
GVL-effect. Patients transplanted from MD received CSA, short
MTX and rabbit ATG. The recommended conditioning regimens
were TBI1VP16 for patients . 2 years; in children younger than
2 years, TBI was substituted by busulfan and cyclophosphamide.
Unmanipulated bone marrow was used in 73% of MSD- and
MD-SCT as recommended by the protocol. No significant differ-
ence in the occurrence of acute and chronic GVHD was observed:
after MSD-SCT: 20% of patients did not develop any aGVHD,
37% had grade I, 31% grade II, 4% grade III and 4% grade IV. Af-
ter MD-SCT, 26% had no GVHD, 39% grade I, 27% grade II, 5%
grade III and 3% grade IV. Limited cGVHD was observed in 7%
vs. 8% and extensive cGVHD in 16% vs. 5% after MSD and MD
